FDA Approves Lyrfigtu in FGFR2 Cholangiocarcinoma

Company Elevar Therapeutics Event Type FDA Approval Modality Small Molecule (Selective FGFR2 Kinase Inhibitor) Asset Lirafugratinib (Lyrfigtu) Target FGFR2 Disease Area FGFR2 Fusion/Rearrangement Cholangiocarcinoma Summary The FDA approved lirafugratinib, branded Lyrfigtu, for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2…